Genome-engineering technologies for modeling and treatment of cystic fibrosis
- PMID: 36917892
- DOI: 10.1016/j.advms.2023.02.003
Genome-engineering technologies for modeling and treatment of cystic fibrosis
Erratum in
-
Corrigendum to "Genome-engineering technologies for modeling and treatment of cystic fibrosis" [Adv Med Sci (2023 Sept) 68(1) 111-120].Adv Med Sci. 2025 Mar;70(1):229. doi: 10.1016/j.advms.2025.01.009. Epub 2025 Feb 12. Adv Med Sci. 2025. PMID: 39952431 No abstract available.
Abstract
Cystic fibrosis (CF) is an autosomal recessive disease caused by defects in the CF transmembrane conductance regulator (CFTR) protein. Due to the genetic nature of the disease, interventions in the genome can target any underlying alterations and potentially provide permanent disease resolution. The current development of gene-editing tools, such as designer nuclease technology capable of genome correction, holds great promise for both CF and other genetic diseases. In recent years, Cas9-based technologies have enabled the generation of genetically defined human stem cell and disease models based on induced pluripotent stem cells (iPSC). In this article, we outline the potential and possibilities of using CRISPR/Cas9-based gene-editing technology in CF modeling.
Keywords: CRISPR; Cystic fibrosis; Prime editing; Stem cell-based disease modeling; hiPSC.
Copyright © 2023 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
